Stepping Down Asthma Treatment: How and When

Linda Rogers and Joan Reibman

Abstract

Purpose of Review—Guidelines suggest that asthma medication should be reduced once asthma control is sustained. Moderate dose inhaled corticosteroids (ICS) can typically be reduced, but questions remain about the lowest effective ICS dose and the role of non-ICS controllers in treatment reduction. Long acting beta agonist (LABA) safety concerns have created controversy about how to step down patients on ICS/LABA therapy. This review will focus on the current status of these issues.

Recent findings—Intermittent ICS treatment, often in fixed combination with short-acting beta agonist, is an emerging strategy for control of mild asthma. Addition of leukotriene modifiers, LABAs, and omalizumab to ICS can allow for reduced ICS dosing. Doses of ICS that control symptoms may be inadequate to control exacerbations. Reducing ICS dose before discontinuing LABAs may be the more effective approach for patients on combination therapy.

Summary—Use of non-ICS controllers allow for ICS dose reduction with superior outcomes. Tapering of ICS prior to LABA discontinuation may be the favored approach for patients on ICS/LABA therapy, but an understanding of long-term outcomes and further safety data are required. The lowest ICS dose that adequately controls both asthma impairment and risk remains to be determined.

Keywords

asthma; step-down; inhaled corticosteroids; long-acting beta agonists

Introduction: why consider reducing asthma treatment?

Asthma guidelines focus on achieving and maintaining asthma control and balancing the risk of medications with control of disease (1, 2). They suggest that once symptoms are controlled for at least 3 months, therapy can be reduced to the lowest dose that maintains control. Despite these recommendations, questions remain about when and how to reduce asthma therapy. Benefits of inhaled corticosteroids (ICS) are well established, and adverse effects are uncommon at low and moderate doses (3). However, concerns about adverse effects remain, particularly with sustained high doses, and include osteoporosis, adrenal axis suppression, cataracts, hoarseness, dysphonia, oral candidiasis, and dermal thinning and bruising. Recent links of ICS to diabetes and pneumonia are cause for concern and require further investigation (**4–6). HIV patients on antiretroviral therapy and ICS can have significant systemic absorption and adverse effects (7). Ongoing concerns in children
include continued evidence of reduced growth velocity without an ultimate impact on adult height (8, 9). Apart from concerns about adverse effects of higher doses of ICS, safety concerns about long acting beta agonists (LABAs) create questions about the optimal way to reduce combination ICS/LABA therapy (10). Carefully monitored therapy reduction trials can clarify disease severity and reduce over-treatment. This review will discuss the current state of knowledge of how one should reduce therapy when asthma control is sustained.

**Can daily low dose ICS be reduced or stopped in mild to moderate persistent asthma?**

Once on low dose therapy, the risk of adverse effects of ICS is low (3, 4, 11, 12). However, patients and some providers still have doubts about ICS safety, leading to the desire to reduce or stop these medications (13, 14). When mild asthma is controlled, ICS can often be reduced by 50%, but reducing therapy is less successful with rapid medication tapering and in moderate to severe disease (15–18). Roughly 50% of children and adults will redevelop symptoms within 1–12 months if ICS is stopped. (16–19). Seasonal effects are noted, with greater success weaning in spring and summer, and more failure in the fall (20). In adults with persistent asthma, the ability to achieve sustained discontinuation of ICS with good control is rare. (21).

More recently, the utility of biomarkers such as sputum eosinophilia (22, 23), exhaled nitric oxide (24, 25) and suppression of bronchial hyperreactivity (BHR) (26, 27) have been considered as tools to guide step-down of asthma therapy. Results are inconclusive, and even the best studied of these approaches, the fraction of exhaled nitric oxide (FeNO), cannot consistently predict which patients tolerate reduced therapy (28). Sputum eosinophilia has fared the best as a biomarker of loss of control, but access to biomarker monitoring is not widely available in primary care settings where most mild to moderate asthmatics receive their care (28).

The use of ICS on an “as needed” basis either alone or paired in the same inhaler with a short acting beta agonist may minimize ICS exposure. Step-down from daily ICS to symptom-driven use of fixed dose combination ICS (beclomethasone) and short-acting beta agonist (SABA) was as effective with a lower ICS dose over 6 months compared to daily ICS (29). Questions remain: will this strategy remain effective over time? In the TREXA study, 288 children ages 5–18 stabilized on 80 mcg beclomethasone daily, were stepped down to either daily ICS + additional rescue ICS as needed, daily ICS alone, rescue ICS alone, or placebo in a 44 week study. Exacerbations were lower in the daily ICS (28%, 18–40, p=0.03), combined (31%, 21–43, p=0.07), and rescue (35%, 24–47, p=0.07) groups compared to placebo (49%) (9). Treatment failure occurred in 23% (95% CI 14–43) of the placebo group, compared with 5.6% (1.6–14) in the combined (p=0.012), 2.8% (0–10) daily (p=0.009), and 8.5% (2–15) in the rescue (p=0.024) groups. Overall daily therapy had the best outcomes but rescue therapy was better than placebo and may reflect real world patient behavior (30).

In summary, reduction of ICS dose is often successful in well-controlled mild asthma. Long-term cessation of ICS can be achieved at times in children, but is rarely successful in adults.
Few biomarkers accurately determine which patients can have therapy reduced and these techniques are often not available in many practice settings. Approaches using low dose ICS plus additional as-needed ICS, or as-needed ICS/SABA combination require further study.

**Stepping down ICS with use of non ICS anti-inflammatory controllers**

When escalating therapy in uncontrolled asthma, addition of non-steroid agents is favored over increasing to high dose ICS for most patients (1, 2). Less data is available to suggest that this approach “works in reverse”-that lowering ICS prior to removing non-steroid drugs is effective at sustaining asthma control. Recent systematic reviews reinforce that LABAs are effective at controlling asthma with lower ICS doses (31). Leukotriene modifiers (LTM) are effective as add-on therapy in asthma not controlled on low-dose ICS, but not as effective as LABAs in adults and possibly children (32, 33). LTM may allow treatment reduction, but complete cessation of ICS with step-down to LTM or LABA alone is associated with a significant loss of asthma control compared to maintenance of ICS (34–36).

There is ample data documenting that omalizumab (anti-IgE) allows reduced ICS dosing. A 2011 systematic review including eight trials and 3429 patients found that omalizumab treated patients were able to reduce their ICS by 50% or discontinue it entirely (*37). In the ICATA study, inner city children with moderate to severe asthma treated with omalizumab plus guidelines-based treatment experienced a 30–48% reduction in exacerbations, including elimination of seasonal peaks, and better control on less ICS and LABA use (*38). While perhaps justified in moderate to severe disease, enthusiasm for this approach must by tempered by the fact that omalizumab has an average wholesale price of $4000-$20000 per year (39). Given that risk of clinically significant long term side effects of low to moderate dose ICS are low, and the modest median ICS dose reduction observed in pooled omalizumab data (median reduced ICS=141 ug budesonide), use of an expensive, resource intensive medication to taper ICS beyond low to moderate dose may not be warranted.

**Stepping down fixed dose combination therapy: reduce ICS or stop LABA?**

One of the most common dilemmas currently faced by practicing physicians is how to reduce ICS/LABA once asthma is controlled. Guidelines recommend a two-step approach: reducing the ICS by 50% and maintaining the LABA, and stopping the LABA if control is sustained with low dose ICS (2). In February 2010, in the context of ongoing debates about LABA safety, the U.S. Food and Drug Administration recommended that LABAs be used for the shortest duration of time required to control asthma and that LABA therapy should be discontinued if possible once asthma control is achieved (40). Regulatory agencies worldwide have not issued a similar recommendation (41). This recommendation has been interpreted to suggest that LABA should preferentially be discontinued prior to lowering ICS, which is in conflict with at least some guidelines (2). To date, some limited data is available comparing these two methods of reducing fixed dose combination therapy, and published studies on this issue are outlined in Table 1.

Reducing ICS dose prior to discontinuing LABAs is supported by several early studies where the addition of LABA to ICS allowed a reduction in ICS dose without loss of asthma control.
Steroid naïve patients with moderate persistent asthma controlled on Fluticasone/ Salmeterol (FSC) 250/50 2x daily were randomized to a 12-week step-down comparing Fluticasone (FP) 250 2x daily vs. FSC 100/50 2 x daily (43). Peak expiratory flow (PEF), the primary endpoint, was maintained in the FSC100/50 group but decreased slightly in FP group. The proportion of patients with well-controlled asthma, a secondary endpoint, was reduced in both groups compared to 250/50, but remained higher in FSC vs. FP. More recently, patients uncontrolled on low dose ICS but controlled on FSC 100/50 for 4 weeks, were either continued on FSC, or stepped down to either same dose FP alone (100 mcg), salmeterol alone (50 mcg), or montelukast alone. FSC was superior for all endpoints (morning PEF, FEV\textsubscript{1}, symptom scores, and likelihood of remaining in the study) (36).

Similarly, in a 6 month trial of patients well-controlled on FSC 250/50 2x daily who were stepped down to FSC 100/50 or FP 250 2x daily, FSC 100/50 was better than FP at maintaining lung function and symptom control (44). FSC 100/50 was non-inferior to continuing FSC 250. The withdrawal rate in the FP group (20%) was double that of either FSC 250 (11%) or FSC 100 (9%). Recently, Reddel et al stepped down patients from FSC 500 2x daily to either FP 500 2x daily or progressively lower dose FSC at 8-week intervals. No difference was found in the primary endpoint (mean FP dose), but the FSC group achieved a lower final ICS dose than the FP group (*45). Finally, in a complex retrospective study of a large managed care claims database, patients stepped down from higher to lower dose FSC compared to FP alone had less SABA use (30%, 1.72 vs. 2.48, p=0.001), 26% lower risk of systemic corticosteroid use (24% vs. 32%, p=0.006), 48% lower risk of an asthma-related hospitalization or ED visit (3.8% vs. 7.4%, p=0.01), and higher refill persistence rates compared with FP (*46). Although data so far suggest improved outcomes maintaining LABA during step-down, given the short step-down phases in most studies (12–24 weeks) and use of primary outcomes such as PEF rather than composite measures of control or exacerbation rates, a definitive answer awaits further study. Efficacy studies such as these are always underpowered to address the issue of LABA safety, a critical issue in weighing risks vs. benefits of asthma therapies. A best estimate of the risk of adverse effects of LABA is important, is an area of significant controversy that may or may not be clarified with upcoming U.S. FDA mandated LABA safety mega-trial (47).

More recent trials of adjustable and maintenance dosing of combination Budesonide and Formoterol (Bud/Form) suggest that adjustable vs. fixed therapy may be associated with equal symptom control at lower ICS doses (48). In a complex study that simultaneously compared the effects of lowering ICS, removing LABA, and once vs. twice daily ICS dosing, twice-daily Bud/Form generally fared better than once daily ICS or ICS/LABA. Combination therapy once or twice daily fared better than ICS alone (49). Enthusiasm for this approach has been somewhat hampered by LABA safety concerns, although a recent meta-analysis did not show an increased risk of adverse events compared with fixed dosing of ICS/LABA (50). Further studies of adjustable and maintenance dosing of Bud/Form as a means of reducing medication once asthma is controlled seem warranted.
Is stepping down beyond moderate dose ICS in adults and low dose ICS in children necessary?

Once asthma control is achieved and sustained, how low should the ICS dose be reduced? Low and moderate dose ICS do not differ in terms of symptom control, but moderate dose ICS may have a slight advantage in terms of lung function (FEV₁ in adults but not children) and at reducing exacerbations (51). Good data suggests that the long-term safety profile of low to moderate dose ICS is favorable (3, 12, 52). In adults with persistent asthma, continuation of moderate dose (FSC 250) ICS/LABA resulted in marginally better symptom control and lung function compared to adjustable and maintenance Bud/Fom, but a striking 50% lower exacerbation rate (53). At the end of one year, both groups ended up on just under 500ug daily of either FP or Bud, respectively. This study suggests that patient-dictated adjustment of medication according to symptoms slightly lowers ICS exposure, but possibly at the cost of a higher exacerbation rate. It also suggests that there is a minimum daily ICS dose needed to prevent exacerbations, at least in adults. The suggestion has been made to use low dose ICS and then increase ICS at the first signs of an exacerbation. Data evaluating this approach show that doubling ICS does not prevent exacerbations (54). It seems that once control is lost, it may not be easily regained. These findings highlight the critical need for long-term step-down studies in both children and adults. If the tradeoff of reduced ICS results in additional exacerbations per year, any benefit gained by ICS reduction may be offset by greater exposure to systemic steroids. In adults, where asthma remission is uncommon, and co-morbid conditions abound, the addition of even one extra course of oral steroids per year over many years may carry more risk of adverse events than maintenance of moderate-dose ICS. In terms of risk of accelerated decline of lung function, prevention by ICS is currently not supported by data and further study is needed (11, 55). A key study would be a long term study along the lines of the Childhood Asthma Management Program study, including both children and adults and comparing reducing ICS vs. maintaining stable dosing and evaluating long term outcomes and adverse effects (11).

Conclusion

Although step-down of controller medication to the lowest dose which controls asthma is an appropriate goal, many unanswered questions remain regarding how to best accomplish this, and what the ultimate “lowest” dose should be. Current recommendations for step-down of therapy do not account for the heterogeneity of asthma, do not make clear distinctions based on disease severity, and do not sufficiently incorporate consideration of disease risk. Current data is overrepresented with short-term studies that may underestimate risk of exacerbations on lower medication dosing and may overstate the benefits of lower dosing compared to risks. More data is needed regarding the ideal duration of control prior to tapering, and the best approach to stepping down patients with severe asthma, particularly those on moderate to high dose ICS/LABA. It is unclear if the outcomes of clinical trials, where patients undergo careful monitoring, is representative of outcomes that can be achieved in general practice settings. Pragmatic clinical trials that recreate typical practice may be needed for better answers.
Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BHR</td>
<td>bronchial hyperreactivity</td>
</tr>
<tr>
<td>Bud/Form</td>
<td>Budesonide/Formoterol combination inhaler</td>
</tr>
<tr>
<td>FeNO</td>
<td>fraction of exhaled nitric oxide</td>
</tr>
<tr>
<td>FEV₁</td>
<td>forced exhaled volume in 1 second</td>
</tr>
<tr>
<td>FP</td>
<td>Fluticasone propionate inhaler</td>
</tr>
<tr>
<td>FSC</td>
<td>Fluticasone/Salmeterol combination inhaler</td>
</tr>
<tr>
<td>ICATA</td>
<td>Inner City Anti-IgE Therapy for Treating Asthma Mechanistic Study</td>
</tr>
<tr>
<td>ICS</td>
<td>inhaled corticosteroids</td>
</tr>
<tr>
<td>LABA</td>
<td>long acting beta-agonist</td>
</tr>
<tr>
<td>LTM</td>
<td>leukotriene modifier</td>
</tr>
<tr>
<td>PEF</td>
<td>peak expiratory flow rate</td>
</tr>
<tr>
<td>SABA</td>
<td>short-acting beta-agonist</td>
</tr>
<tr>
<td>TREXA</td>
<td>Treating Children to Prevent Exacerbations Study</td>
</tr>
</tbody>
</table>

References

* of special interest

** of outstanding interest

4**. O’Byrne PM, Pedersen S, Carlsson LG, Radner F, Thoren A, Peterson S, et al. Risks of pneumonia in patients with asthma taking inhaled corticosteroids. Am J Respir Crit Care Med. 2011 Mar 1; 183(5):589–95. A retrospective analysis of all trials of at least 3 months using inhaled Budesonide supports that there was no increased of pneumonia with use of inhaled Budesonide, and suggesting that concerns raised regarding risks of pneumonia in COPD trials may not be similar in asthma. [PubMed: 20889908]
9. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011 Feb 19; 377(9766):650–7. A 44-week study in children ages 5–18 provides added support to other possible use of intermittent inhaled corticosteroids in children with mild persistent asthma. Children on daily therapy still fared best, but low treatment failure rate in the as needed ICS group and comparable exacerbation rates are notable. This study also reaffirms that high exacerbation rates (49%) and treatment failure rates (23%) in children with persistent asthma treated with SABA alone. Impaired growth velocity was observed in children on low dose ICS. [PubMed: 21324520]


28**. Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2010 Oct 11. A systematic review of both FeNO and sputum eosinophilia supports the role of tailoring asthma therapy to sputum eosinophilia monitoring in decreasing asthma exacerbations. Conversely, monitoring of FeNO levels was not effective in improving asthma outcomes in children and adults. The authors conclude that neither technique can be recommended in practice at this time due to lack of technical expertise in the case of sputum eosinophilia, and lack of data in the case of FeNO.


45*. Reddel HK, Gibson PG, Peters MJ, Wark PA, Sand IB, Hoyos CM, et al. Down-titration from high-dose combination therapy in asthma: Removal of long-acting beta(2)-agonist. Respir Med. 2010 Aug; 104(8):1110–20. An addition to several published studies suggesting that when reducing therapy for patient on combination ICS/LABA, reducing ICS is superior to initial discontinuation of LABA. Combination patients were able to achieve lower ICS doses, and the author proposed that many patients in the trial were being over-treated on FSC 500/50. [PubMed: 20430604]

46*. Hagiwara M, Delea TE, Stanford RH, Stempel DA. Stepping down to fluticasone propionate or a lower dose of fluticasone propionate/salmeterol combination in asthma patients recently initiating combination therapy. Allergy Asthma Proc. 2010 May-Jun;31(3):203–10. A claims data base study finding fewer hospitalizations, ED visits, fewer courses of oral corticosteroids, and lower short acting beta agonists use when ICS is tapered prior to LABA discontinuation compared to continuation of same dose ICS with discontinuation of LABA. Greater refill persistence with FSC vs. FP was observed. [PubMed: 20534183]

47. Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs). United States Food and Drug Administration (FDA); Apr 15. 2011


### Table 1

<table>
<thead>
<tr>
<th>Study/Reference</th>
<th>Design</th>
<th>N</th>
<th>Duration</th>
<th>Population</th>
<th>Intervention</th>
<th>Primary outcome</th>
<th>Results</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koenig 2008 (36)</td>
<td>RDBPG</td>
<td>647</td>
<td>16 weeks</td>
<td>Uncontrolled on low-moderate ICS but controlled on FSC 100/50</td>
<td>Step-down to FP100, SAL 50 or Montelukast</td>
<td>PEF</td>
<td>Control deteriorated in all step-down groups</td>
<td></td>
</tr>
<tr>
<td>Fowler 2002 (42)</td>
<td>RDBPG</td>
<td>39</td>
<td>12 weeks</td>
<td>Mod-severe asthma</td>
<td>1000 BDP BID X 4 weeks then BDP 200 2 x daily or FSC 100/50 2 x daily</td>
<td>PC20</td>
<td>Doubling dose improvement in MCT with FSC greater than either BDP dose</td>
<td>Lung function and QOL better on FSC vs BDP step-down</td>
</tr>
<tr>
<td>Bateman 2006 (43)</td>
<td>RDBPG</td>
<td>484</td>
<td>24 weeks</td>
<td>Moderate asthma, well-controlled</td>
<td>FSC 250/50 stepped down to FSC 100/50 vs FP 250</td>
<td>PEF</td>
<td>PEF lower in FP vs FSC</td>
<td>Symptoms, rescue albuterol and control better on FSC than FP</td>
</tr>
<tr>
<td>Godard 2008 (44)</td>
<td>RDBPG</td>
<td>473</td>
<td>6 months</td>
<td>Well controlled on FSC 250/50</td>
<td>Decrease to FSC 100/50 vs FP 250</td>
<td>PEF</td>
<td>FSC 100/50 similar to 250/50 but better than FP 250</td>
<td></td>
</tr>
<tr>
<td>Reddel 2010 (45)</td>
<td>RDBPG</td>
<td>82</td>
<td>13 months</td>
<td>FSC 500/50</td>
<td>500/50 vs FP 500 and down titrated every 8 weeks</td>
<td>Mean daily FP dose</td>
<td>No difference in mean daily dose FP but final dose lower in FSC</td>
<td>Question if patients were over treated</td>
</tr>
</tbody>
</table>

RDBPG= randomized, double blinded, parallel group; BDP= beclomethasone dipropionate; ICS= inhaled corticosteroids; BHR= bronchial hyperreactivity; CS= corticosteroids